Ketamine Addiction After One Therapeutic Dose: How Rare Is It?
Ketamine and its S-enantiomer esketamine (sold as Spravato) are now established treatments for treatment-resistant depression and acute suicidality. The standard safety pitch from sponsors and clinics: at single sub-anesthetic doses, in supervised settings, addiction risk is minimal. A new case report in BJPsych Open documents a patient for whom that pitch failed catastrophically — and …